Assetmark, Inc Fibrogen Inc Transaction History

Assetmark, Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$18.57 - $35.68 $241 - $463	-13 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$40.47 - $45.5 $161 - $182	4 Added 44.44%	13 $1,000
Q2 2020 Aug 11, 2020	SELL	$32.57 - $42.83 $32 - $42	-1 Reduced 10.0%	9 $0
Q1 2020 May 12, 2020	SELL	$23.3 - $45.96 $582 - $1,149	-25 Reduced 71.43%	10 $0
Q3 2019 Nov 13, 2019	BUY	$36.98 - $48.45 $1,294 - $1,695	35 New	35 $1,000
Q1 2018 May 16, 2018	SELL	$45.35 - $61.65 $408 - $554	-9 Closed	0 $0
Q4 2017 Feb 13, 2018	BUY	$41.95 - $60.1 $125 - $180	3 Added 50.0%	9 $0
Q3 2017 Nov 08, 2017	BUY	$33.4 - $53.9 $200 - $323	6	6 $0

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Assetmark, Inc, based on Form 13F filings with the SEC.

Stay updated on Assetmark, Inc with notifications on news.